Background: Hemorrhagic infiltration of the common aortopulmonary adventitia is an infrequent complication of acute aortic dissection, most frequently Stanford type A. The radiological interpretation of this finding may be a diagnostic challenge. The objective of this multicenter case series is to review the radiological and pathological findings of hemorrhagic infiltration of the aortopulmonary adventitia secondary to acute aortic dissection, and to describe the pathophysiology underlying this complication.
Material And Methods: The study includes 20 cases of aortic dissection with hemorrhagic infiltration of the aortopulmonary adventitia. These are 17 cases with computed tomography (CT) data obtained from 5 academic centers. Three other cases were retrieved through a search of autopsy reports. Clinical, radiological and pathological data were collected.
Results: Linear foci of moderately increased attenuation were seen along the wall of the proximal pulmonary arteries in 4 cases on unenhanced CT. Contrast-enhanced CT showed soft-tissue thickening along these walls in all imaging cases, with some degree of narrowing of the lumen of the pulmonary arteries. Peribronchovascular ground-glass opacities or consolidation were present in 4 cases.
Conclusion: Hemorrhagic infiltration of the common aortopulmonary adventitia is an infrequent complication of acute type A aortic dissection. The radiologist should be aware of its pathophysiology and imaging findings in order to make a prompt diagnosis in an urgent setting.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejrad.2015.11.025 | DOI Listing |
Ann Plast Surg
December 2024
Plastic, Reconstructive and Aesthetic Surgery Department and Burn Unit, São João University Hospital, Porto, Portugal.
Background: Previous studies demonstrated the effectiveness and safety of tranexamic acid (TXA) in several surgical specialties. Recent publications suggested that TXA may also be beneficial in plastic surgery, including breast procedures.
Objective: The aim of this study is to evaluate the impact of TXA in reduction mammaplasty by assessing several intraoperative and postoperative outcomes and the safety of its administration.
Am J Case Rep
January 2025
Department of Anatomic Pathology and Cytopathology, University Hospital "Dr. José Eleuterio González", Monterrey, Mexico.
BACKGROUND Primary cardiac malignancies are extremely rare, with an incidence of 0.07% on autopsy series. Primary sarcomas represent up to 95% of malignant neoplasms, with myxofibrosarcomas accounting for only 10%.
View Article and Find Full Text PDFCurr Treat Options Oncol
January 2025
Breast Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Breast cancer metastasizing to the central nervous system (CNS) encompasses two distinct entities: brain metastases involving the cerebral parenchyma and infiltration of the leptomeningeal space, i.e., leptomeningeal disease.
View Article and Find Full Text PDFClin Cancer Res
December 2024
Baylor University Medical Center, Dallast, Texas, United States.
Purpose: Brentuximab vedotin (BV) is hypothesized to selectively deplete T regulatory cells (Tregs) that express CD30 and re-sensitize tumors to anti-(PD-1) therapy. This study evaluated responses to BV+pembrolizumab post PD-1 and explored corresponding biomarkers.
Methods: 55 patients with metastatic non-small cell lung cancer (NSCLC) and 58 with metastatic cutaneous melanoma received ≥1 dose of BV+pembrolizumab.
Cancer Med
January 2025
Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Background: Immune checkpoint inhibition therapies have provided remarkable results in numerous metastatic cancers, including mismatch repair-deficient (dMMR) colorectal cancer (CRC). To evaluate the potential for PD-1 blockade therapy in a large population-based cohort, we analyzed the tumor microenvironment and reviewed the clinical data and actualized treatment of all dMMR CRCs in Central Finland province between 2000 and 2015.
Material And Methods: Of 1343 CRC patients, 171 dMMR tumors were identified through immunohistochemical screening.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!